Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants.
- Published In:
- Diabetes, obesity & metabolism, 26(12), 5805-5811 (2024)
- Authors:
- Gabe, Maria B N, Fuhr, Rainard, Sinn, Angela, Eliasen, Astrid, Berthelsen, Kasper K, Kuhlman, Anja B, Bækdal, Tine A, Nejad, Ayna B
- Database ID:
- RPEP-08227
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-08227APA
Gabe, Maria B N; Fuhr, Rainard; Sinn, Angela; Eliasen, Astrid; Berthelsen, Kasper K; Kuhlman, Anja B; Bækdal, Tine A; Nejad, Ayna B. (2024). Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants.. Diabetes, obesity & metabolism, 26(12), 5805-5811. https://doi.org/10.1111/dom.15951
MLA
Gabe, Maria B N, et al. "Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants.." Diabetes, 2024. https://doi.org/10.1111/dom.15951
RethinkPeptides
RethinkPeptides Research Database. "Cagrilintide is not associated with clinically relevant QTc ..." RPEP-08227. Retrieved from https://rethinkpeptides.com/research/gabe-2024-cagrilintide-is-not-associated
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.